Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Cecchi

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Scientific Reports|May 27, 2024
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancerAnsh Kapil, Andreas Spitzmüller, Nicolas Brieu, et al.
Journal of Translational Medicine|October 23, 2014
Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladderBrian K McNeil, Maximiliano Sorbellini, Robert L Grubb, et al.
Frontiers in Oncology|December 29, 2022
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profilingFrancesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, et al.
Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|July 2, 2014
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissueDaniel V T Catenacci, Wei-Li Liao, Sheeno Thyparambil, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Scientific Reports|May 27, 2024
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancerAnsh Kapil, Andreas Spitzmüller, Nicolas Brieu, et al.
Journal of Translational Medicine|October 23, 2014
Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladderBrian K McNeil, Maximiliano Sorbellini, Robert L Grubb, et al.
Frontiers in Oncology|December 29, 2022
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profilingFrancesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, et al.
Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|July 2, 2014
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissueDaniel V T Catenacci, Wei-Li Liao, Sheeno Thyparambil, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Pageof 5